Fig. 3From: Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapyPeripheral a PD-1 occupancy and b receptor occupancy (RO) of patients treated with nivolumab. MEL = melanoma; PD-1 = programmed death–1; pts = patientsBack to article page